Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Tracheal Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

Bevacizumab 40Paclitaxel 35Carboplatin 28pembrolizumab 21Cyclophosphamide 15Specimen Handling 14Cisplatin 13olaparib 11Blood Specimen Collection 11niraparib 10fludarabine 10Magnetic Resonance Spectroscopy 9Drug Therapy 9liposomal doxorubicin 8Topotecan 8Taxes 8Gemcitabine 8Biopsy 8Fulvestrant 7Doxorubicin 6cemiplimab 5abemaciclib 5Surveys and Questionnaires 5Standard of Care 5Injections 5Fluorouracil 5Cytoreduction Surgical Procedures 5trastuzumab deruxtecan 4mirvetuximab soravtansine 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ovarian Neoplasms × Combined Modality Therapy × Clear all
NCT05206890 2022-01-26

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Tongji Hospital

Recruiting
490 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡